I don't know. Every study is different, depending on the number of patients. But they are expensive in terms of the resources. Also, at the sides you have to have expert people within the company. You have epidemiologists. You have groups of people looking at the signals that might be emerging.
This is an expensive effort. That's why we need to ensure that there is international cooperation, so that eventually the study could be manageable at the national level.